The pharmacogenetics of antiplatelet drugs.
Platelets play a pivotal role in coronary heart disease and atherothrombotic events, and thus antiplatelet therapy is commonly used to treat cardiovascular disease. Unfortunately, the benefits of this approach are limited, and a large proportion of treated patients will suffer a new thrombotic event, either within the first few weeks following stent implantation or in the follow-up period after myocardial infarction. This lack of clinical benefit may be related to a heterogeneous response to antiplatelet drugs among individuals. Recently, the field of pharmacogenetics has tried to identify gene variants in order to explain tile observed heterogeneity in patient responses to drugs. This review explores the genetic influences on antiplatelet drug efficacy by analyzing the modulating role of different genetic polymorphisms on individual responses to antiplatelet therapy.
Marín
Francisco
F
Servicio de Cardiologia, Hospital Universitario Virgen de la Arrixaca, Madrid-Cartagen s/n El Palmar, Murcia, 30008 Spain. fcomarino@hotmail.com
Roldán
Vanessa
V
González-Conejero
Rocío
R
Corral
Javier
J
D006801:Humans; D009203:Myocardial Infarction / Q000235:genetics / Q000517:prevention & control*; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors